|drug138||Acacia Senegal Wiki||1.00|
|D055370||Lung Injury NIH||0.18|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
To study the efficacy of Gum Arabic as an immuno modulator and anti-inflammatory agent among COVID 19 seropositive patients..Half of participants will receive Gum Arabic and the other half will receive placebo
Description: Changes of the level of Tumor Necrosis Factor (TNF), interleukin IL8,IL6,IL10 from the baseline valuesMeasure: Mean change from baseline score of Immune Response to end of the trial ( Time Frame: up to 4 weeks ) Time: 4 weeks
Description: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placeboMeasure: Mortality rate Time: from the date of assignment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to two months
Description: Change of viral load from BaselineMeasure: Determine viral load in each patient Time: 4 weeks
Description: Time of discharge from hospital after full recoveryMeasure: clinical improvement and hospital discharge Time: from the date of assignment until the date of hospital discharge for the last assigned case, whichever comes first, assessed up to two months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports